E2810 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
This research is being done to determine whether taking an oral drug known as pazopanib (VotrientÂ®) will reduce the risk of the cancer recurring in the future.
Generally healthy adults with renal cell carcinoma may be eligible to participate if you: Have no evidence of disease after surgery, Have not received prior chemotherapy, Have normal laboratory results and blood pressure, Have normal ECG results, and Are not pregnant or nursing.
Eligible subjects will receive either pazopanib by mouth each day or a matching placebo (an inactive substance that looks like the study drug, but contains no medication). You will be randomly assigned, like flipping a coin, to either regimen. You or your doctor will not be able to choose the regimen. You will continue to take your assigned study drug for about 1 year. You will have imaging done every 3 months to monitor your disease.
11/28/2014 04:03 AM